Vrablik M - Search Results

1

Satny M, Hubacek JA, Vrablik M. Satny M, et al. Among authors: vrablik m. Curr Atheroscler Rep. 2021 Dec 1;23(12):80. doi: 10.1007/s11883-021-00977-6. Curr Atheroscler Rep. 2021. PMID: 34851454 Review.

2

T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals.

Horínek A, Vráblík M, Ceska R, Adámková V, Poledne R, Hubacek JA. Horínek A, et al. Among authors: vrablik m. Atherosclerosis. 2003 Apr;167(2):369-70. doi: 10.1016/s0021-9150(03)00022-4. Atherosclerosis. 2003. PMID: 12818421 No abstract available.

3

Ser19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people.

Vrablík M, Horínek A, Ceska R, Adámková V, Poledne R, Hubacek JA. Vrablík M, et al. J Med Genet. 2003 Aug;40(8):e105. doi: 10.1136/jmg.40.8.e105. J Med Genet. 2003. PMID: 12920097 Free PMC article. No abstract available.

4

New variants in the apolipoprotein AV gene in individuals with extreme triglyceride levels.

Hubácek JA, Adámková V, Ceska R, Poledne R, Horínek A, Vráblík M. Hubácek JA, et al. Among authors: vrablik m. Physiol Res. 2004;53(2):225-8. Physiol Res. 2004. PMID: 15046561 Free article.

5

Hypertriglyceridemia: interaction between APOE and APOAV variants.

Hubacek JA, Horínek A, Skodova Z, Adamkova V, Ceska R, Zlatohlavek L, Vráblík M. Hubacek JA, et al. Among authors: vrablik m. Clin Chem. 2005 Jul;51(7):1311-3. doi: 10.1373/clinchem.2005.048439. Clin Chem. 2005. PMID: 15976129 No abstract available.

6

[Genetics of dyslipidemia--yesterday, today, and tomorrow].

Hubácek JA, Vrablík M. Hubácek JA, et al. Among authors: vrablik m. Vnitr Lek. 2007 Apr;53(4):371-6. Vnitr Lek. 2007. PMID: 17578168 Review. Czech.

7

[Statin pharmacokinetics].

Hubácek JA, Adámková V, Zídková K, Ceska R, Zlatohlávek L, Stulc T, Horínek A, Vrablík M. Hubácek JA, et al. Among authors: vrablik m. Vnitr Lek. 2008 Jan;54(1):62-7. Vnitr Lek. 2008. PMID: 18390119 Review. Czech.

8

APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels.

Hubacek JA, Wang WW, Skodová Z, Adámková V, Vráblík M, Horínek A, Stulc T, Ceska R, Talmud PJ. Hubacek JA, et al. Among authors: vrablik m. Clin Chem Lab Med. 2008;46(6):773-7. doi: 10.1515/CCLM.2008.160. Clin Chem Lab Med. 2008. PMID: 18601597

9

MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe.

Vrablik M, Ceska R, Adamkova V, Peasey A, Pikhart H, Kubinova R, Marmot M, Bobak M, Hubacek JA. Vrablik M, et al. Hum Genet. 2008 Dec;124(5):553-5. doi: 10.1007/s00439-008-0577-6. Epub 2008 Oct 23. Hum Genet. 2008. PMID: 18946681

10

Impact of apolipoprotein A5 variants on statin treatment efficacy.

Hubacek JA, Adamkova V, Prusikova M, Snejdrlova M, Hirschfeldova K, Lanska V, Ceska R, Vrablik M. Hubacek JA, et al. Among authors: vrablik m. Pharmacogenomics. 2009 Jun;10(6):945-50. doi: 10.2217/pgs.09.17. Pharmacogenomics. 2009. PMID: 19530961

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters